Get the Stockscreener App
23.64
4.65%
1.05
After Hours:
23.70
0.06
+0.25%
Beam Therapeutics Inc stock is traded at $23.64, with a volume of 1.62M.
It is up +4.65% in the last 24 hours and down -30.65% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$22.59
Open:
$22.5
24h Volume:
1.62M
Relative Volume:
1.11
Market Cap:
$2.36B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-13.06
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-13.79%
1M Performance:
-30.65%
6M Performance:
-9.22%
1Y Performance:
-32.15%
1-Day Range:
$22.50
$24.32
1-Week Range:
$22.50
$28.34
52-Week Range:
$20.84
$36.75
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
23.64 | 2.36B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily
3 Gene Therapy Stocks to Watch Amid Industry Turmoil - Schaeffers Research
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study - MSN
Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? - Insider Monkey
BEAM Down Despite Positive Initial Data From Genetic Disorder Study - MSN
Wedbush Research Analysts Raise Earnings Estimates for BEAM - Defense World
Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World
Citi lifts Beam Therapeutics stock price target to $64 - Investing.com India
Citi lifts Beam Therapeutics stock price target to $64 By Investing.com - Investing.com Australia
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock By Investing.com - Investing.com South Africa
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock - Investing.com Australia
Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial - CRISPR Medicine News
Beam Therapeutics stock target holds at $37 on positive trial data - Investing.com Canada
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market - Dealbreaker
Beam Therapeutics stock target holds at $37 on positive trial data By Investing.com - Investing.com South Africa
Beam Therapeutics: Promising Phase 1 Results for BEAM-302 in AATD, Hold Rating Due to Long-term Efficacy Uncertainty - TipRanks
Beam Therapeutics (NASDAQ:BEAM) Receives “Buy” Rating from HC Wainwright - Defense World
BMO Capital maintains Outperform on Beam Therapeutics stock - MSN
Wainwright holds Beam stock Buy rating, $80 target after trial data - Investing.com
In Vivo Base Editing Gets Boost with Positive Initial Data Announced by Beam Therapeutics - Genetic Engineering & Biotechnology News
Proficio Capital Partners LLC Makes New $406,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Beam Therapeutics, Lennar, Redfin - TradingView
Beam Therapeutics (NASDAQ:BEAM) Upgraded by Scotiabank to “Sector Outperform” Rating - Defense World
Beam Therapeutics’ (BEAM) Outperform Rating Reaffirmed at Wedbush - Defense World
Beam Therapeutics (NASDAQ:BEAM) Upgraded by Jones Trading to Buy Rating - Defense World
Scotiabank Upgrades Beam Therapeutics (BEAM) - Nasdaq
Beam Gets Important Proof Of Concept For AATD Therapy - Citeline News & Insights
Beam Therapeutics: Single-Base Editing Seems To Work - Seeking Alpha
Beam drops 9% on phase 1/2 data for genetic lung disease candidate - Seeking Alpha
JonesResearch upgrades Beam Therapeutics to Buy on de-risking data - TipRanks
Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright - TipRanks
Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target - TipRanks
Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target - Marketscreener.com
Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst - TipRanks
Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? - Insider Monkey
Beam launches $500m financing on base-editing trial data - pharmaphorum
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity - Benzinga
Beam Therapeutics Prices $500 Million Share, Warrant Offering -March 10, 2025 at 08:15 am EDT - Marketscreener.com
Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition - STAT
Beam Therapeutics rises on early-stage trial results for gene editing therapy - TradingView
Beam Therapeutics Announces Positive Initial Data For BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq
Beam Therapeutics’ BEAM-302 Shows Promising Efficacy and Safety in AATD Treatment, Earning Buy Rating - TipRanks
Beam Therapeutics stock soars on positive BEAM-302 trial data - Investing.com
Beam Therapeutics stock soars on positive BEAM-302 trial data By Investing.com - Investing.com Canada
Beam Therapeutics Shares Surge on Promising Trial Data - TipRanks
Beam Therapeutics Reports Positive Phase 1/2 Trial Data - TipRanks
Beam Therapeutics Reprots Positive Initial Phase 1/2 Data For BEAM-302 In AATD - Nasdaq
Beam Therapeutics BEAM-302 Was Well Tolerated At All Dose Levels -March 10, 2025 at 06:11 am EDT - Marketscreener.com
Beam Therapeutics Reports Promising Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Clinical Trial - Nasdaq
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation - The Manila Times
Beam Therapeutics announces ‘positive’ data from study of BEAM-302 - TipRanks
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):